Tevogen Bio (NASDAQ:TVGN) Stock Price Down 1.6% – What’s Next?

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) traded down 1.6% during mid-day trading on Wednesday. The company traded as low as $6.40 and last traded at $6.9990. 2,500 shares were traded during mid-day trading, a decline of 57% from the average daily volume of 5,756 shares. The stock had previously closed at $7.11.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a research report on Thursday. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tevogen Bio has a consensus rating of “Reduce” and an average target price of $100.00.

Tevogen Bio Price Performance

The firm has a market capitalization of $45.02 million, a P/E ratio of -1.49 and a beta of 0.19. The firm’s 50 day moving average is $7.01 and its two-hundred day moving average is $7.12.

Tevogen Bio (NASDAQ:TVGN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.53) by $1.01.

About Tevogen Bio

Tevogen Bio is a clinical-stage biotechnology company developing targeted T-cell therapies for viral diseases and cancer. The company’s approach is designed to use healthy-donor immune cells to create “off-the-shelf” treatments intended to selectively recognize and eliminate diseased cells while limiting damage to healthy tissue.

Tevogen’s lead investigational therapy, TVGN 489, is an allogeneic, virus-specific cytotoxic T-cell therapy being developed for conditions associated with Epstein-Barr virus, including multiple sclerosis.